Enhertu Approved in China for HER2 GEJ Cancer
Enhertu Receives China Approval for HER2-Positive Gastric Cancer In a significant advancement for cancer treatment in China, Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted approval by the National Medical Products Administration (NMPA). The approval is for adult patients battling locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This decision … Read more